Breaking News

RBS First-Half Profit Doubles, Shares Gain as Much as 10% in London
Tweet TWEET

Atossa Genetics Announces National Agreement With Network Provider FedMed

Atossa Genetics Announces National Agreement With Network Provider FedMed 
More Than 40 Million Americans Have Access to FedMed's National
Provider Network 
SEATTLE, WA -- (Marketwire) -- 03/13/13 --  Atossa Genetics, Inc.
(NASDAQ: ATOS), The Breast Health Company(TM), has entered into a
contractual agreement with FedMed, Inc., one of the largest
proprietary Preferred Provider Organization (PPO) networks in the
U.S., for diagnostic laboratory testing. FedMed's network is
comprised of more than 550,000 providers, including 4,000 hospitals
and more than 60,000 ancillary facilities, serving over 40 million
Americans.  
Atossa's agreement with FedMed will give FedMed's participating
providers and its clients' members greater access to Atossa's tests,
including the ForeCYTE Breast Health Test and the ArgusCYTE Breast
Health Test. 
"There is a significant unmet clinical need in the medical community
for more effective ways to identify women at high risk of breast
cancer," stated Steven C. Quay, M.D., Ph.D., FCAP, Chairman, CEO &
President of Atossa Genetics. "Our agreement with FedMed will help
ensure that more doctors and their patients have access to the
ForeCYTE Breast Health Test, a risk stratification test akin to the
cervical Pap smear, and the ArgusCYTE Breast Health Test, a blood
test for recurrence targeted at the 3.2 million breast cancer
survivors in the U.S." 
Dr. Quay added, "At Atossa, our goal is to help physicians manage
their patients' breast health by offering a suite of products and
services that address the most pressing clinical decisions. Armed
with better information, physicians will be able to customize
individualized treatment plans to reduce women's risk of breast
cancer or cancer recurrence, to improve patient therapeutic
compliance and ultimately to decrease the overall cost of care."  
About Atossa Genetics, Inc. 
Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company(TM),
is based in Seattle, WA, and is focused on preventing breast cancer
through the commercialization of patented diagnostic medical devices
and patented, laboratory developed tests (LDT) that can detect
precursors to breast cancer up to eight years before mammography, and
through research and development that will permit it to commercialize
treatments for pre-cance
rous lesions. 
The National Reference Laboratory for Breast Health (NRLBH), a wholly
owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified
high-complexity molecular diagnostic laboratory located in Seattle,
WA, that provides the patented ForeCYTE Breast Health Test and the
ArgusCYTE Breast Health Test. 
About the ForeCYTE Breast Health Test 
The ForeCYTE Breast Health Test provides personalized information
about the 10-year and lifetime risk of breast cancer for women
between ages 18 and 73. It involves collecting a specimen of nipple
aspirate fluid, or NAF, using our patented Mammary Aspirate Specimen
Cytology Test, or MASCT, System. The NAF specimen is collected by a
physician and returned to our CLIA-certified laboratory. We study the
patient's NAF specimen and use a proprietary molecular and cellular
biomarker test that detects basal or luminal cells to identify the
presence of atypical ductal hyperplasia, or ADH, which is considered
a precursor to breast cancer. If ADH is detected, steps can be taken
to reduce the risk of breast cancer. 
About the ArgusCYTE Breast Health Test 
The ArgusCYTE Breast Health Test provides information to help inform
breast cancer treatment options and to help monitor potential
recurrence. It involves collecting a blood specimen from a patient
using our patented blood collection tube and submitting it to
Atossa's CLIA-certified laboratory. The AugusCYTE test can monitor
breast cancer distant recurrence by obtaining a "liquid biopsy" or
blood sample, and analyzing it for the presence of circulating tumor
cells, which can then be analyzed to determine the expression of
Estrogen Receptor/Progesterone Receptor, or ER/PR, and Human
Epidermal Growth Factor Receptor, or Her2, in those cells, a
predictor of the cancer's sensitivity to existing treatment options.
The presence of circulating tumor cells in the blood sample may also
serve as an early indicator of the recurrence of breast cancer and
the data obtained from the ArgusCYTE sensitivity analysis may help
physicians better select which treatment options to use with a
particular patient.  
About FedMed, Inc. 
FedMed is a National Provider Network and Healthcare Financial
Services Organization. FedMed has developed innovative programs and
services for the healthcare provider community in conjunction with
large payors of healthcare services. FedMed's objective is to provide
significant measurable benefits to providers not available from other
provider networks and managed care organizations. Traditional
networks and payors are eager to negotiate and take discounts, but
less than eager to pay on time and quantify the value of their
contracts. FedMed's programs have been created to specifically
address these challenges. For more information, visit
www.fedmedinc.com. 
Forward-Looking Statements 
Except for the historical information contained herein, the matters
set forth in this press release, including statements regarding
Atossa's plans, regulatory actions, Atossa's responses to regulatory
actions, expectations, projections, potential opportunities, goals
and objectives are forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are subject to
risks and uncertainties that may cause actual results to differ
materially from the anticipated or estimated future results,
including the risks and uncertainties associated with actions by the
FDA, regulatory clearances, responses to regulatory matters, Atossa's
ability to continue to manufacture and sell its products, the
efficacy of Atossa's products and services, the market demand for and
acceptance of Atossa's products and services and other risks detailed
from time to time in the Atossa's, filings including its registration
statement form S-1 filed January 28, 2013, as amended and
supplemented from time to time. All forward-looking statements are
qualified in their entirety by this cautionary statement, and Atossa
undertakes no obligation to revise or update any forward-looking
statement to reflect events or circumstances after the issuance of
this press release. 
Contact: 
Atossa Genetics, Inc.
Steven C. Quay, M.D., Ph.D., FCAP 
Chairman, President and CEO of Atossa Genetics and 
Director of the National Reference Laboratory for Breast Health
800-351-3902
Steven.Quay@atossagenetics.com 
Dante Ruffalo
Dian Griesel Inc.
212-825-3210
druffalo@dgicomm.com